Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $27,388.04 in Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 659 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $27,388.04. Following the transaction, the insider now directly owns 94,481 shares in the company, valued at $3,926,630.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $134,123.84.
• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total transaction of $10,983.96.

Twist Bioscience Stock Up 0.2 %

Shares of TWST opened at $45.52 on Friday. The stock has a 50-day moving average of $43.65 and a two-hundred day moving average of $45.43. Twist Bioscience Co. has a one year low of $15.85 and a one year high of $60.90.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience in the 3rd quarter worth approximately $43,992,000. Point72 Asset Management L.P. boosted its holdings in shares of Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after acquiring an additional 613,057 shares during the last quarter. Fred Alger Management LLC increased its stake in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after acquiring an additional 575,080 shares during the period. New York State Common Retirement Fund raised its holdings in shares of Twist Bioscience by 1.8% during the third quarter. New York State Common Retirement Fund now owns 482,606 shares of the company’s stock worth $21,804,000 after purchasing an additional 8,529 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its position in Twist Bioscience by 63.0% during the second quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock valued at $19,152,000 after purchasing an additional 150,260 shares during the period.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Barclays reduced their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. JPMorgan Chase & Co. increased their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.